Multiple Myeloma Treatment Market Size Report 2034 | GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi

DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Discover Key Insights into the Multiple Myeloma Market with DelveInsight's In-Depth Report @ Multiple Myeloma Market Size- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Multiple Myeloma Market Report
• In February 2025-Hoffmann-La-Roche:- CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.
• In February 2025:- AbbVie:- Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
• In February 2025:- AstraZeneca:- This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM. This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents.
• In February 2025:- Pfizer:- This is a single-arm elranatamab post-trial access study. Participants will receive elranatamab. All participants will receive elranatamab until disease progression, unacceptable toxicity, withdrawal of consent, study termination or, elranatamab becomes commercially accessible in the participant's country.
• In February 2025:- Kite:- The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug.
• In February 2025:- Celgene:- A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
• According to DelveInsight, Multiple Myeloma market is expected to grow at a decent CAGR by 2034.
• The leading Multiple Myeloma companies such as GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi, Karyopharm Therapeutic, Janssen Biotech, Bristol Myers Squibb, AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners, Chipscreen Biosciences, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Cartesian Therapeutics, AstraZeneca, MorphoSys AG/I-Mab Biopharma and others.
• Promising Multiple Myeloma Therapies such as Venetoclax (ABT-199), Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M), REGN5458, Iberdomide (CC-220), Blenrep (Belantamab Mafodotin /GSK2857916), Abecma (Idecabtagene vicleucel/bb2121/ ide-cel), Pepaxto (melflufen/ melphalan flufenamide), Sarclisa (Isatuximab), Xpovio (Selinexor), Darzalex (Daratumumab) and others.

Stay ahead in the Multiple Myeloma Therapeutics Market with DelveInsight's Strategic Report @ Multiple Myeloma Market Outlook- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Epidemiology Segmentation in the 7MM
• Total incident cases of multiple myeloma,
• Total symptomatic cases of multiple myeloma,
• Gender-specific cases of multiple myeloma,
• Age-specific cases of multiple myeloma,
• Transplant-eligible cases of multiple myeloma,
• Treated patient pool across all lines of therapies

Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Prevalence- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Marketed Drugs

• CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
CARVYKTI is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. In April 2024, Johnson & Johnson announced that the US FDA approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with RRMM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. In February 2022, Johnson & Johnson Innovative Medicine announced that the US FDA had approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T cells and G protein-coupled receptor class C group 5 member D (GPRC5D), a novel multiple myeloma target which is highly expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as some healthy tissues such as epithelial cells of the skin and tongue. TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Emerging Multiple Myeloma Drugs
• Mezigdomide (CC-92480): Bristol Myers Squibb
Mezigdomide is a highly potent modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Mezigdomide binds to cereblon (CRBN) upon administration, affecting the ubiquitin E3 ligase activity and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T cells. The company is evaluating the drug in different clinical trials in different lines of therapies for treating NDMM and RRMM. In January 2023, the company initiated the Phase III trial of CC-92480 in combination with carfilzomib and dexamethasone (480kd) vs. carfilzomib and dexamethasone in 2L+ participants with RRMM (SUCCESSOR-2). The company is expecting the first approval of mezigdomide by 2026-2027.

• Linvoseltamab (REGN5458): Regeneron
Linvoseltamab is a BCMAxCD3 bispecific antibody in patients with RRMM. It is designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T cells, bridging them together and activating T-cell killing of the cancer cell. The drug is designed to closely resemble natural human antibodies, using Regeneron's proprietary 'human antibody mouse' technology (VelocImmune) and 'full-length bispecific antibody' platform (VelociBi). The linvoseltamab clinical development program includes a Phase III confirmatory trial in patients with R/R MM (LINKER-MM3) that is currently enrolling. Additional trials in earlier lines of therapy and stages of disease are planned or underway, including a Phase I/II trial in the first-line setting, a Phase II trial in high-risk smoldering MM, and a Phase II trial in monoclonal gammopathy of undetermined significance. Apart from that, a Phase I trial of linvoseltamab in combination with a Regeneron CD38xCD28 costimulatory bispecific in MM is also planned. In February 2024, the company announced that the US FDA had accepted for priority review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with RRMM that has progressed after at least three prior therapies. Moreover, the target action date for the FDA decision is August 22, 2024.

Get In-Depth Knowledge on Multiple Myeloma Market Trends and Forecasts with DelveInsight @ Multiple Myeloma Treatment Market- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Drugs Market
The existing multiple myeloma treatment is mainly dominated by classes such as Proteasome Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, Nuclear export inhibitors, CAR-T cell therapy, and Bi-specific antibodies. Apart from these classes, Histone Deacetylase (HDAC) inhibitors were also included in the treatment regimen, but now it has been withdrawn from the US market.

Learn more about the emerging Multiple Myeloma therapies & key companies @ Multiple Myeloma Clinical Trials, Drugs and Therapies- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple Myeloma Market Report
• Coverage- 7MM
• Multiple Myeloma Companies- GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi, Karyopharm Therapeutic, Janssen Biotech, Bristol Myers Squibb, AbbVie, Takeda Pharmaceutical, Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners, Chipscreen Biosciences, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Cartesian Therapeutics, AstraZeneca, MorphoSys AG/I-Mab Biopharma and others.
• Multiple Myeloma Therapies- Venetoclax (ABT-199), Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M), REGN5458, Iberdomide (CC-220), Blenrep (Belantamab Mafodotin /GSK2857916), Abecma (Idecabtagene vicleucel/bb2121/ ide-cel), Pepaxto (melflufen/ melphalan flufenamide), Sarclisa (Isatuximab), Xpovio (Selinexor), Darzalex (Daratumumab) and others.
• Multiple Myeloma Market Dynamics: Multiple Myeloma Market Drivers and Barriers
• Multiple Myeloma Market Access and Reimbursement and Unmet Needs

Unlock Strategic Insights with DelveInsight's Comprehensive Multiple Myeloma Market Report @ Multiple Myeloma Market Drivers and Barriers- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Executive Summary
3. Multiple Myeloma Competitive Intelligence Analysis
4. Multiple Myeloma Market Overview at a Glance
5. Multiple Myeloma Disease Background and Overview
6. Multiple Myeloma Patient Journey
7. Multiple Myeloma Epidemiology and Patient Population
8. Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple Myeloma Unmet Needs
10. Key Endpoints of Multiple Myeloma Treatment
11. Multiple Myeloma Marketed Products
12. Multiple Myeloma Emerging Therapies
13. Multiple Myeloma Seven Major Market Analysis
14. Attribute Analysis
15. Multiple Myeloma Market Outlook (7 major markets)
16. Multiple Myeloma Access and Reimbursement Overview
17. KOL Views on the Multiple Myeloma Market
18. Multiple Myeloma Market Drivers
19. Multiple Myeloma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.